Changsong Qi
First author of the CT041 trials that showed a CAR-T can shrink gastric and pancreatic tumours.
Changsong Qi led the clinical conduct of the Claudin 18.2 CAR-T (CT041) phase 1 and phase 2 studies with Lin Shen, and works on immunotherapy for gastric cancer.
| Title | Journal | Year |
|---|---|---|
| Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results | Nature Medicine | 2022 |
Pages like this
not linked directly; found by shared links- PersonLin Shen
Shares Satricabtagene autoleucel, Peking University Cancer Hospital, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- CompanyCARsgen Therapeutics
Shares Satricabtagene autoleucel, Peking University Cancer Hospital, Gastric & gastro-oesophageal junction cancer.
- IdeaIn vivo CAR-T against solid-tumour antigens
Shares Satricabtagene autoleucel, Claudin 18.2, Gastric & gastro-oesophageal junction cancer, CAR-T cell therapy.
- PairingCLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression
Shares Satricabtagene autoleucel, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- CompanyRemeGen
Shares Peking University Cancer Hospital, Gastric & gastro-oesophageal junction cancer.
- CompanyKeymed Biosciences (KYM Biosciences)
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- IdeaPeritoneal-directed therapy for gastric cancer
Shares Satricabtagene autoleucel, Gastric & gastro-oesophageal junction cancer.
- InstitutionHenan Cancer Hospital
Shares Gastric & gastro-oesophageal junction cancer, CAR-T cell therapy.